Homing frequency of human T cells inferred from peripheral blood depletion kinetics after sphingosine-1-phosphate receptor blockade - 29/04/13
![](/templates/common/images/entites/lowast.gif)
![](/templates/common/images/entites/lowast.gif)
![](/templates/common/images/mail.png)
Supported by a grant from Novartis AG, Basel, Switzerland, and by the Swiss Multiple Sclerosis Society. C.H. and P.G. are supported by grants from the Swiss National Science Foundation (31003A_135677/1 and PB323630-128881, respectively). |
|
Disclosure of potential conflict of interest: M. Mehling has received research support from the Novartis Research Foundation and the Swiss MS Society and is employed by University Hospital Basel. V. Brinkmann is employed by Novartis. L. Kappos has received research support from the Novartis Research Foundation (Basel, Switzerland), Bayer, Biogen Idec, Merck Serono, Novartis, Teva, Roche, the Swiss MS Society, the European Union, the Gianni Rubatto Foundation, the Roche Research Foundation, and the Novartis Research Foundation; is a member of the Actelion Data and Safety Monitoring Committee; is on the advisory boards for Advancell, Allozyne, and Wyeth; is chair of the Bayer, Novartis, and Roche Steering Committees; is member and chair of the Biogen Idec advisory board; is chair of the Genmab, MediciNova, Santhera, and UCB Data and Safety Monitoring Committee; is chair of the Merck Serono advisory board; is a member of the Merck Serono Steering Committee; is a member of the Teva advisory board and Steering Committee; has received consultancy fees from Novonordisk, Peptimmune, Glenmark, BioMarin, GeNeuro SA, Eli Lilly, CSL Behring, Bayhill, and Sanofi Aventis; has received lecture fees from Bayer, Biogen Idec, Merck Serono, Novartis, Sanofi Aventis, Roche, and Teva; and has received payment for the development of educational presentations from Bayer, Merck Serono, Novartis, Sanofi Aventis, Roche, Teva, and UCB. C. Hess has received research support from the Swiss National Science Foundation and Research Hub Basel University-Roche and is employed by University Hospital Basel. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 131 - N° 5
P. 1440 - mai 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?